|
Andy, Neisseria meningitidis vaccine is not a great candidate for the USA market. The numbers are now more visible because of the decrease in the Haemophilus influenzae cases. But it will be hard to fit in the schedule, the case could be made but not an easy one. The use in older groups to provide herd immunity could be argue for. Also, it could be use in countries were disease is more rampant. Last summer West Africa meningitis cases were more than 250,000 with about 40,000 deaths. The company could provided to this countries with the help of the World Health Organization, usually the US and other rich countries will pay for it, they will aid the poorer countries, and they usually buy in bulk from the company and provide the chance for some decent return, it is still a profit. But, they are getting ready for the US serotypes, not the rest of the world, limiting the ability to provided to other countries. It should be cheap enough to manufacture to recover development investment. If they are (most probably) working on it with the FDA and the NIH coordination they have more chances. |
